Abstract: The present application relates to N-chlorinated cationic compounds of Formula I or a salt thereof, and associated compositions and methods of use as antimicrobial agents.

Abstract: Antimicrobial lubricant compositions are disclosed. The antimicrobial lubricant compositions are particularly useful in providing antimicrobial capability to a wide-range of medical devices. The compositions include an oil lubricant. Representative lubricants may include polydimethyl siloxane, trifluoropropyl copolymer polysiloxane, and a copolymer of dimethylsiloxane and trifluoropropylmethylsiloxane. The compositions include rheology modifiers as necessary. The compositions also include antimicrobial agents, which may be selected from a wide array of agents. Representative antimicrobial agents include of aldehydes, anilides, biguanides, bis-phenols, quaternary ammonium compounds, cetyl pyridium chloride, cetrimide, alexidine, chlorhexidine diacetate, benzalkonium chloride, and o-phthalaldehyde.

Abstract: Provided are monoquaternary ammonium compounds which are modulators of nicotinic acetylcholine receptors. Also provided are methods of using the compounds for modulating the function of a nicotinic acetylcholine receptor, and for the prevention and/or treatment of central nervous system disorders, substance use and/or abuse, and or gastrointestinal tract disorders.

Abstract: An antimicrobial fiber bearing an anionic functional group, and a method of producing it wherein at least a part of the anionic functional group forms a quaternary ammonium salt and at least another part thereof forms an antimicrobial metal salt. The quaternary ammonium salt is preferably a cetylpyridinium salt, and the antimicrobial metal salt is preferably a zinc salt. The fiber is preferably a carboxyalkylated cellulose fiber. An antimicrobial fiber product comprising the antimicrobial fiber.

Abstract: The present invention relates to compositions and methods for decreasing the infectivity, morbidity, and rate of mortality associated with a variety of pathogenic organisms and viruses. The present invention also relates to methods and compositions for decontaminating areas colonized or otherwise infected by pathogenic organisms and viruses. Moreover, the present invention relates to methods and compositions for decreasing the infectivity of pathogenic organisms in foodstuffs.

Abstract: A multi-purpose contact lens care solution having high antimicrobial activity comprising, in an aqueous liquid medium, cetylpyridinium chloride and a non-ionic surfactant. In one embodiment of the invention, the non-ionic surfactant is a poly(oxypropylene)-poly(oxyethylene) block copolymer. The solution may optionally also include additional antimicrobial components, a buffer component, a viscosity inducing component, a surfactant, taurine, propylene glycol and/or a tonicity component. This solution additionally prevents losses in ocular tissue membrane integrity during contact lens wear.

Abstract: Provided are bis-quaternary ammonium compounds which are modulators of nicotinic acetylcholine receptors. Also provided are methods of using the compounds for modulating the function of a nicotinic acetylcholine receptor, and for the prevention and/or treatment of central nervous system disorders, substance use and/or abuse, and or gastrointestinal tract disorders.

Abstract: Addition salts of 2,4?-dimethyl-3-piperidinopropiophenone (tolperisone) are described, wherein the salt is formed with an acid R—COOH and wherein R is the organic group of a physiologically compatible organic acid. Described also are processes for the preparation of these addition salts, the use thereof for pharmaceutical preparations and pharmaceuticals containing these addition salts.

Abstract: A concentrated quaternary ammonium compound (QAC) solution comprising a QAC with a concentration from greater than about 10% by weight and at least one solubility enhancing agent, such as an alcohol, is disclosed. A diluted QAC solution is used to contact food products to prevent microbial growth on the food products from a broad spectrum of foodborne microbial contamination. A method of contacting the food products with the dilute QAC for an application time of at least 0.1 second is disclosed. The foods that can be treated by this method are meat and meat products, seafood, vegetables, fruit, dairy products, pet foods and snacks, and any other food that can be treated and still retain its appearance and texture. One of the treatment methods is spraying and misting the QAC solutions on the food products for an application time of at least 0.1 second to prevent broad spectrum foodborne microbial contamination.

Abstract: This disclosure relates to inventive methods for inactivating viral pathogens comprising providing a virucidal composition comprising a liquid media containing less than 1% weight per volume of a quaternary ammonium compound, such as cetylpyridinium chloride and between 0% and 0.5% weight per volume of citric acid, and contacting a surface targeted for disinfection with the virucidal composition. This disclosure further relates to inventive virucidal compositions comprising a liquid media, a quaternary ammonium compound, such as cetylpyridinium chloride, at a concentration of less than 1% weight per volume, citric acid at a concentration of between 0.0% and 0.5% weight per volume, an extender, and an enhancer.

Abstract: The present invention relates to salts comprising bis(trifluoromethyl)imide anions and saturated, partially or fully unsaturated, heterocyclic cations, to a process for the preparation thereof, and to the use thereof as ionic liquids.

Abstract: The present invention includes compounds of pyridinium salts and methods of their use for agricultural purposes. The present invention also relates to methods of controlling fungi and/or bacteria.

Abstract: A concentrated quaternary ammonium compound (QAC) solution comprising a QAC with a concentration from greater than about 10% by weight and at least one solubility enhancing agent, such as an alcohol, is disclosed. A diluted QAC solution is used to contact food products to prevent microbial growth on the food products from a broad spectrum of foodborne microbial contamination. A method of contacting the food products with the dilute QAC for an application time of at least 0.1 second is disclosed. The foods that can be treated by this method are meat and meat products, seafood, vegetables, fruit, dairy products, pet foods and snacks, and any other food that can be treated and still retain its appearance and texture. One of the treatment methods is spraying and misting the QAC solutions on the food products for an application time of at least 0.1 second to prevent broad spectrum foodborne microbial contamination.

Abstract: The invention relates to a method for inhibiting and/or preventing formation of cancer metastases and secondary malignant cancers by administration to a subject of an effective amount of a quaternary pyridinium salt of formula I wherein R? is selected from the group consisting of H, OH, CONH2, COCH3, R? is selected from the group consisting of H, CH3, R?? represents H or CH3, and X? is a pharmaceutically acceptable counterion.

Abstract: Disclosed are neuroblastoma tumor-initiating cell inhibiting compositions comprising chemical entities capable of affecting neuroblastoma tumor-initiating cells. Pharmaceutical preparations that include these chemical entities are also provided for the treatment of neuroblastoma. These pharmaceutical preparations are suitable for the treatment of humans, and are particularly suited for the treatment of children of 12 years of age or younger having neuroblastoma. The compositions and pharmaceutical preparations posses reduced normal cell cytotoxicity. The compositions and pharmaceutical preparations may be used alone or together with other conventional neuroblastoma preparations as part of a clinical regimen in the treatment and management of neuroblastoma.

Abstract: Pyridinium cationic lipids useful as non-viral gene delivery agents are disclosed. The agents are prepared by reaction of pyrylium salts with primary amines. Also disclosed are methods of trasfectind cells using the pyridinium cationic lipids as gene transfer agents.

Abstract: Microbicidal compositions including (a) cyanodithiocarbimate and (b) an N-alkyl heterocyclic compound; a triazole compound or salt thereof or metal complex thereof; a microbicide with an activated halogen atom or a formaldehyde releasing compound; 1,4-bis(bromoacetoxy)-2-butene; 2-(thiocyanomethylthio)benzothiazole; a methylene-bis(thiocyanate); a halogenated acetophenone; a halopropynl compound; an iodosulfone; a phenol; a halocyanoacetamide compound and/or a quaternary ammonium compound are described. Components (a) and (b) can be present in a synergistically effective amount to control the growth of at least one microorganism. Methods for controlling the growth of microorganisms with the compositions are also disclosed.

Abstract: A method for minimizing microbial contamination of contact lenses during the handling of the lenses. The method comprises instructing a person that wears contact lenses to wash their hands prior to the handling of the contact lenses with a wash composition. The wash composition includes one or more surfactants selected from the group consisting of non-ionic, cationic, amphoteric or zwitterionic surfactants, and optionally, an anionic surfactant. The wash composition also includes an antimicrobial agent that is compatible with ocular tissue. The invention is also directed to a kit for to assist contact lens wearers with the care maintenance of their lenses. The kit includes the wash composition and a multipurpose contact lens solution. The wash composition is suitable for use with the multipurpose contact lens solution.

Abstract: Inhibitors of HIV reverse transcriptase which are useful for the treatment of HIV infection. Exemplars of the invention are compounds of the formula wherein the substituents are as defined in the following table R1 R2 R4 R5 R8a F CF3 Me H —OH F CF3 Cl H —OH F CF3 Me H —O—CH2CO2H Cl CN Cl H —OH.

Abstract: Cetylpyridinium salt of diclofenac.

Abstract: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

Abstract: The present invention relates to Halogenated amino acid analogues for use in diagnosis, which compounds have the general formula (I) wherein: R is (C1–C6) alkyl optionally substituted with thioether or ether oxygen atom when n=0, or a substituted aromatic or heteraromatic ring when n=1–6; and m=0 or 1; and X is a halogen atom.

Abstract: Disclosed are nicotinanilide-N-oxide compounds, methods for their production, pharmaceutical compositions which include these compounds, and methods for their use in various therapies.

Abstract: Compositions and methods of treating a retroviral infection in an afflicted host and/or inhibiting replication of a retrovirus involve administering a therapeutically effective amount of the following compound of formula I: A-L-B??(I) wherein A is a substituted or unsubstituted aryl compound, substituted or unsubstituted piperidyl, or substituted or unsubstituted thiopheneyl; L is sulfonyl, sulfinyl or thio; and B is a substituted or unsubstituted aromatic nitrogen containing heteroaryl compound; or pharmacologically acceptable acid-addition and base-addition salts thereof.

Abstract: A fungicidal composition and method of treating plant diseases using a compound of formula

Abstract: Compounds that are dual aP2/k-FABP inhibitors are provided having the formula wherein A, B, X, Y, R1, R2 and R3 are as described herein. A method is also provided for treating diabetes and related diseases, especially Type II diabetes, employing dual aP2/k-FABP inhibitors alone or in combination with at least one other antidiabetic agent such as metformin, glyburide, troglitazone and/or insulin.

Abstract: A description is given of compounds of the formula in which R1 and R2 independently of one another are halogen, C1-C6alkyl, halo-C1-C6alkyl, C1-C6alkoxy, halo-C1-C6alkoxy, or SF5, R3 is hydrogen, OH, halogen, C1-C6alkoxy or —O—C(?O)—C1-C6alkyl, R4 is for example hydrogen, halogen, C1-C6alkyl, halo-C1-C6alkyl, C1-C6alkoxy, halo-C1-C6alkoxy or SCN; R5 and R6 independently of one another are for example hydrogen, C1-C12alkyl, halo-C1-C12alkyl, C2-C12alkenyl, halo-C2-C12alkenyl or C2-C12alkynyl; and q is 0 or 1; and, where appropriate, E/Z isomers, E/Z isomer mixtures and/or tautomers, each in free form or in salt form; a process for the preparation of these compounds and their use, pesticide compositions whose active ingredient is selected from these compounds, or an agrochemically useable salt thereof, a process for preparing these compositions, and their use, plant propagation material treated with these compositions, and a method of combating pests.

Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.

Abstract: The invention relates to new piperazinyl-substituted pyridylalkane, alkene, and alkine acid amides substituted with saturated or one or several-fold unsaturated hydrocarbon residue in the carboxylic acid group according to the general formula (I) as well as methods for the production of these compounds, medicaments containing these and their production as well as their therapeutic use, especially as cytostatic agents and immunosuppressive agents, for example in the treatment or prevention of various types of tumors and control of immune reactions such as autoimmune diseases.

Abstract: The invention features quaternary ammonium compounds of formula I, described herein, and their use in treating asthma, chronic obstructive pulmonary disorder, allergic rhinitis, and infectious rhinitis.

Abstract: The invention relates to insecticidal mixtures for protecting plants against attack by pests comprising (a) compounds of the formula (I) ?in which W, X, Y, Z, A, B, D and G are each as defined in the disclosure, and (b) agonists or antagonists of nicotinic acetylcholine receptors.

Abstract: A concentrated quaternary ammonium compound (QAC) solution comprising a QAC with a concentration from greater than about 10% by weight and at least one solubility enhancing agent, such as an alcohol, is disclosed. A diluted QAC solution is used to contact food products to prevent microbial growth on the food products from a broad spectrum of foodborne microbial contamination. A method of contacting the food products with the dilute QAC for an application time of at least 0.1 second is disclosed. The foods that can be treated by this method are meat and meat products, seafood, vegetables, fruit, dairy products, pet foods and snacks, and any other food that can be treated and still retain its appearance and texture. One of the treatment methods is spraying and misting the QAC solutions on the food products for an application time of at least 0.1 second to prevent broad spectrum foodborne microbial contamination.

Abstract: Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formula (Ia) and (Ib) where R2, R3, R4, R5, R6, R7, R8, Het and X are defined herein. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds.

Abstract: The invention relates to novel cationic amphiphiles having an aromatic ring comprising at least one nitrogen atom. The cationic amphiphiles are particularly useful for the introduction of biologically compounds such as DNA, RNA, proteins and the like into eukaryotic cells. The cationic amphiphiles are represented by the following basic formula:(I). Characteristic is that R1 and R2 ?are single C6-C24 carbon chains. For the mode of action it is assumed that R1 folds back over the aromatic ring towards R2.

Abstract: The present invention discloses an organic ionic compound having anti-viral activity and the method for antagonizing virus in vitro by putting the compounds in contact with the virus.

Abstract: Highly hydrophilic indole and benzoindole derivatives that absorb and fluoresce in the visible region of light are disclosed. These compounds are useful for physiological and organ function monitoring. Particularly, the molecules of the invention are useful for optical diagnosis of renal and cardiac diseases and for estimation of blood volume in vivo.

Abstract: Compounds and methods are provided for the treatment of disease conditions in which modification of serotonergic receptor activity has a beneficial effect. In the method, an effective amount of a compound is adminstered to a patient in need of such treatment.

Abstract: A method of inhibiting effects of exogenous neurotoxic or neurotoxinic products in warm-blooded animals comprising administering to warm-blooded animals before exposure to said products an inhibitorily effective amount of reversible cholinesterase inhibitor selected from the group consisting of pyridostigmine and physostigmine followed by administration of an inhibitorily effective amount of 2-methyl-1-(1-piperidinyl)-1-(2-thienyl)-cyclohexane in substantially pure racemic, diastereoisomeric or enantiomeric form.

Abstract: Compounds and methods are provided for the treatment of disease conditions in which modification of serotonergic receptor activity has a beneficial effect. In the method, an effective amount of a compound is adminstered to a patient in need of such treatment.

Abstract: The invention relates to new compounds with the general formula I for use as a tool to introduce macromolecules into cells. The invention further relates to compositions for introducing macromolecules into cells, comprising vesicles formed by at least one compound in a solvent. The macromolecule can be incorporated in the vesicles and/or bound to the vesicles or another aggregate of the new compounds.

Abstract: The present invention provides methods of synthesizing and screening inhibitors of bacterial NAD synthetase enzyme, compounds thereof, and methods of treating bacterial and microbial infections with inhibitors of bacterial NAD synthetase enzyme.

Abstract: The present invention provides an excellent acetylcholinesterase inhibitor. That is, it provides an acetylcholinesterase inhibitor comprising a 1-benzylpyridinium salt represented by the following formula: wherein R1, R2, R3 and R4 are the same as or different from each other and each represents a hydrogen atom, a halogen atom, a hydroxyl group, a nitrile group, a C1-6 alkyl group, a C1-6 alkoxy group etc.; R5 represents a hydrogen atom, a halogen atom etc.; the partial structure: is a group represented by the formula >C(R6)—CH2— (wherein R6 is a hydrogen atom or a halogen atom) or >C═CH—; X− represents a halide ion or organic sulfonic acid ion; and m is 0 or an integer from 1 to 5.

Abstract: A compound of formula (I): wherein: R1 represents hydrogen, or linear or branched (C1-C6)alkyl optionally substituted by one or more identical or different groups selected from aryl, heteroaryl, cycloalkyl and heterocycloalkyl, represents a saturated ring having from 4 to 7 ring members that may contain, in addition to nitrogen, one or two hetero atoms selected from O, S and —NR3 groups, wherein R3 represents hydrogen or linear or branched (C1-C6)alkyl, n represents an integer such that 1≦n≦6, R2 represents any one of the groups described in the description, their isomers and addition salts thereof with a pharmaceutically acceptable acid or base and medicinal products containing the same are useful as inhibitor of trypsin-related serine proteases and thrombin.

Abstract: There is provided a pharmaceutical composition suitable for topical administration to an eye, the composition comprising (a) an antibiotic antibiotic drug, for example linezolid, in a therapeutically or prophylactically effective drug concentration, (b) as a solubilizing agent, a pharmaceutically acceptable cyclodextrin compound in a concentration sufficient to maintain the drug in solution at such a drug concentration, and (c) as a preservative, cetyl pyridinium chloride. The composition is particularly useful for the treatment and/or prevention of eye infections due to gram positive bacteria.

Abstract: The current invention provides novel thiomolybdate derivatives, methods of making novel thiomolybdate derivatives, pharmaceutical compositions of novel thiomolybdate derivatives, methods of using novel thiomolybdate derivatives to treat diseases associated with aberrant vascularization and methods of using pharmaceutical compositions of thiomolybdate derivatives to treat diseases associated with aberrant vascularization.

Abstract: Niacin and niacin prodrugs are topically administered as suitable formulations to device for impoving the lipid profiles of subjects, preferably humans.

Abstract: As disclosed herein, the present invention provides a compound having the structural formula wherein R1, R2, R3, and R4 are each independently H, or a methyl, halo, trifluoromethyl, nitro, alkyloxy, or acyloxy group, or a pharmaceutically acceptable salt or prodrug thereof. Also disclosed are compounds, compositions, methods and kits for treating, preventing, or inhibiting injuries induced by a vesicant agent, such as bis-2-chloroethylsulfide (HD). Additionally, protectants and decontaminants are disclosed.

Abstract: This application is directed to compounds useful as inhibitors at PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis and chronic obstructuive pulmonary disease, of the formula: where j is 0 or 1 provided that when j is 0, n must be 2; k is 0 or 1; m is 0, 1, or 2; n is 1 or 2; W1 is —O—; or —S(═O)t—, where t is 0, 1, or 2; Y is —C(R1a); Q1 is phenyl or substituted phenyl; Q2 is biphenyl or substituted biphenyl; and the remaining variables are defined as set forth in the specification. This application is also directed to pharmaceutical compositions comprising those compounds and to methods of treating diseases regulated by the activation and degranulation of eosinophils, in particular asthma, chronic bronchitis and chronic obstructive pulmonary disease.

Abstract: A consumable film adapted to adhere to and dissolve in the oral cavity of a warm-blooded animal including humans, comprising at least one water soluble polymer, a taste masking effective amount of a sweetener, and a pharmaceutically active agent having a sufficiently unpleasant taste that it is desirably masked by the sweetener.

Abstract: The invention relates to a compound of formula (I): wherein: A represents pyridine, pyridinium or piperidine R1, R2, R3 and R4 are as defined in the description R5 represents hydrogen, a nitrogen-containing heterocycle or a group of formula (II): R6 represents hydrogen or linear or branched (C1-C6)alkyl. and medicinal products containing the same which are useful in treating pain or deficiencies in memory.